WO2012094615A3 - Use of cav3.1 selective t-type calcium channel antagonists - Google Patents

Use of cav3.1 selective t-type calcium channel antagonists Download PDF

Info

Publication number
WO2012094615A3
WO2012094615A3 PCT/US2012/020518 US2012020518W WO2012094615A3 WO 2012094615 A3 WO2012094615 A3 WO 2012094615A3 US 2012020518 W US2012020518 W US 2012020518W WO 2012094615 A3 WO2012094615 A3 WO 2012094615A3
Authority
WO
WIPO (PCT)
Prior art keywords
type calcium
calcium channel
selective
channel antagonists
prevention
Prior art date
Application number
PCT/US2012/020518
Other languages
French (fr)
Other versions
WO2012094615A2 (en
Inventor
Eckard Weber
Tilman Oltersdorf
Martin Koller
Original Assignee
Zenyaku Kogyo Kabushikikaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zenyaku Kogyo Kabushikikaisha filed Critical Zenyaku Kogyo Kabushikikaisha
Publication of WO2012094615A2 publication Critical patent/WO2012094615A2/en
Publication of WO2012094615A3 publication Critical patent/WO2012094615A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is directed to heterocyclic compounds which are antagonists of T-type calcium channels and which are useful in the treatment and prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to methods of identifying a compound for the treatment and prevention of Alzheimer's Disease by investigating T-type calcium channel blocking activity of the compound.
PCT/US2012/020518 2011-01-07 2012-01-06 Use of cav3.1 selective t-type calcium channel antagonists WO2012094615A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161430827P 2011-01-07 2011-01-07
US61/430,827 2011-01-07
US201161450913P 2011-03-09 2011-03-09
US61/450,913 2011-03-09

Publications (2)

Publication Number Publication Date
WO2012094615A2 WO2012094615A2 (en) 2012-07-12
WO2012094615A3 true WO2012094615A3 (en) 2012-08-30

Family

ID=46457728

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2012/020518 WO2012094615A2 (en) 2011-01-07 2012-01-06 Use of cav3.1 selective t-type calcium channel antagonists
PCT/US2012/020515 WO2012094612A1 (en) 2011-01-07 2012-01-06 Method of treating essential tremor

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2012/020515 WO2012094612A1 (en) 2011-01-07 2012-01-06 Method of treating essential tremor

Country Status (1)

Country Link
WO (2) WO2012094615A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6957460B2 (en) 2015-10-22 2021-11-02 カビオン・インコーポレイテッドＣａｖｉｏｎ， Ｉｎｃ． How to Treat Angelman Syndrome and Related Disorders
US20210128537A1 (en) * 2016-12-21 2021-05-06 Praxis Precision Medicines, Inc. T-type calcium channel modulators and methods of use thereof
EP3585376A4 (en) 2017-02-15 2020-11-25 Cavion, Inc. Calcium channel inhibitors
EP3615521A4 (en) * 2017-04-26 2021-02-17 Cavion, Inc. Methods for improving memory and cognition and for treating memory and cognitive disorders
EP3615010A4 (en) * 2017-04-26 2021-06-30 Cavion, Inc. Methods for treating dravet syndrome
BR112021006398A2 (en) 2018-10-03 2021-07-06 Cavion Inc treatment of essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl) acetamide
CA3146857A1 (en) 2019-07-11 2021-01-14 Praxis Precision Medicines, Inc. Formulations of t-type calcium channel modulators and methods of use thereof
US20220370443A1 (en) * 2021-05-19 2022-11-24 Amyriad Pharma, Inc. Method of treating alzheimer's disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070213267A1 (en) * 2005-09-30 2007-09-13 The Board Of Trustees Of The University Of Illinois Peptides and Calcium Regulation in Mammalian Cells
US20090221554A1 (en) * 2008-02-28 2009-09-03 Zenyaku Kogyo Kabushiki Kaisha Method of treating cognitive impairment
US20100204247A1 (en) * 2007-10-04 2010-08-12 Duffy Joseph L N-substituted oxindoline derivatives as calcium channel blockers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008132139A2 (en) * 2007-04-27 2008-11-06 Ucb Pharma S.A. New heterocyclic derivatives useful for the treatment of cns disorders
CN102369202A (en) * 2008-11-13 2012-03-07 链接医药公司 Azaquinolinone derivatives and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070213267A1 (en) * 2005-09-30 2007-09-13 The Board Of Trustees Of The University Of Illinois Peptides and Calcium Regulation in Mammalian Cells
US20100204247A1 (en) * 2007-10-04 2010-08-12 Duffy Joseph L N-substituted oxindoline derivatives as calcium channel blockers
US20090221554A1 (en) * 2008-02-28 2009-09-03 Zenyaku Kogyo Kabushiki Kaisha Method of treating cognitive impairment

Also Published As

Publication number Publication date
WO2012094615A2 (en) 2012-07-12
WO2012094612A1 (en) 2012-07-12

Similar Documents

Publication Publication Date Title
WO2012094615A3 (en) Use of cav3.1 selective t-type calcium channel antagonists
PH12018500960A1 (en) Processes for preparing isoquinolinones and solid forms of isoquinolinones
HRP20190491T1 (en) 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
MX2020001602A (en) Lfa-1 inhibitor and polymorph thereof.
BR112014014276A2 (en) compound, pharmaceutical composition, method for inhibiting a receptor kinase, and methods for treating conditions, diseases and / or disorders, and pain
WO2012040641A3 (en) Compounds for treating neurodegenerative diseases
WO2014070991A3 (en) Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
MX2014010589A (en) PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE.
EA201390711A1 (en) HYDROXYAMIDE COMPOUNDS OF Pyrimidine As Inhibitors of Protein Deacetylases and Methods for Their Use
EA201391485A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
WO2012173682A3 (en) Compounds and methods for the treatment of isocitrate dehydrognase related diseases
UA113750C2 (en) COMPOSITION (+) - 2- $ 1- (3-ethoxy-4-methoxyphenyl) -2-methanesulfonylethyl] -4-ACETYLAMINOISOINDOLINE-1,3-DIONE
UA113641C2 (en) BETA SECRETASE INHIBITORS
WO2012122058A3 (en) Alkyne substituted quinazoline compound and methods of use
WO2012065102A3 (en) S-t-butyl protected cysteine di-peptide analogs and related compounds
WO2012040636A3 (en) Compounds and methods for treating diseases mediated by protease activated receptors
WO2012002687A3 (en) Methods for treating bipolar disorder
MX2013002851A (en) Inhibitors of notum pectinacetylesterase and methods of their use.
WO2012112674A3 (en) Compounds and methods of use thereof for treating neurodegenerative disorders
MX370253B (en) Compositions of jasmonate compounds and methods of use.
PH12014502541A1 (en) 5-amino [1,4] thiazines as bace 1 inhibitors
WO2008131946A3 (en) Substituted amide derivatives
WO2012174488A3 (en) Agents and methods for treating ischemic and other diseases
MX2013002956A (en) Arylosulfonamides for the treatment of cns diseases.
EP2681209A4 (en) Compounds and methods for the treatment of pain and other disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12732332

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 14/10/2013)

122 Ep: pct application non-entry in european phase

Ref document number: 12732332

Country of ref document: EP

Kind code of ref document: A2